IDRSF Stock Chart & Stats
$7.25
-$0.19(-2.32%)
At close: 4:00 PM EDT
$7.25
-$0.19(-2.32%)
Day’s Range― - ―
52-Week Range$3.50 - $8.19
Previous CloseN/A
Volume3.50K
Average Volume (3M)2.34K
Market Cap
$1.40B
Enterprise Value$3.01B
Total Cash (Recent Filing)$88.69M
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta-0.52
Next Earnings
Oct 29, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding269,779,600
10 Day Avg. Volume2,992
30 Day Avg. Volume2,341
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market Cap2.15
Enterprise Value/Revenue15.06
Enterprise Value/Gross Profit18.60
Enterprise Value/Ebitda-16.53
Forecast
1Y Price Target
$6.91Price Target Upside-4.69% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$263.49M
Bulls Say, Bears Say
Bulls Say
Pipeline BreadthThe proprietary small-molecule pipeline spans cardiovascular, CNS and other therapeutic areas, giving Idorsia several scientific and commercial avenues. This breadth can provide multiple development opportunities over the next few quarters rather than dependence on one indication.
Partnership ModelIdorsia can supplement product sales with upfront payments, development and regulatory milestones, and royalties from partners. This model provides several potential revenue channels and allows larger pharmaceutical companies to support commercialization of selected assets.
Strong Gross MarginAn approximately 81% gross margin indicates that marketed products and other revenue carry substantial gross-profit potential before operating costs. If revenue stabilizes and development spending becomes more efficient, this profile could support improved operating leverage.
Bears Say
Deep Operating LossesExtremely negative EBITDA and net margins show that gross profit is currently insufficient to cover operating and development costs. Persistent losses reduce internal funding capacity and make a durable path to profitability dependent on materially better execution or revenue growth.
Ongoing Cash BurnNegative operating and free cash flow show that the business continues consuming cash rather than funding itself. The pack states ongoing funding will likely be required if trends persist, which can constrain investment choices and increase dependence on external capital.
Stressed Balance SheetMaterially negative equity combined with debt that is large relative to the asset base indicates limited financial flexibility. This stressed capital structure can restrict the company’s ability to absorb setbacks, fund development internally, or manage obligations without additional support.
IDRSF FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was $3.50 and its highest was $8.19 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is $1.40B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 19 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -$0.205 earnings per share for the quarter, beating the consensus estimate of -$0.235 by $0.03.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Overvalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd does not currently pay dividends.
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.33.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 269,779,600 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -$0.205 in its last earnings report, beating expectations of -$0.235. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in IDRSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDRSF Stock 12 Month Forecast
Average Price Target
$6.91
▼(-4.69% Downside)
Technical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Ownership Overview
―
Insiders
3.73% Mutual Funds
― Other Institutional Investors
93.22% Public Companies and
Individual Investors